T1	Treatment 38 96	oral JAK inhibitor tofacitinib (CP-690,550) versus placebo
T2	Treatment 117 140	background methotrexate
T3	Treatment 216 235	methotrexate alone.
T4	Treatment 313 355	oral tofacitinib (CP-690,550) with placebo
T5	Treatment 463 481	methotrexate (MTX)
T6	Treatment 517 533	MTX monotherapy.
T7	Treatment 651 673	placebo or tofacitinib
T8	Treatment 835 839	MTX.
T9	Treatment 1030 1041	tofacitinib
T10	Treatment 1261 1272	for placebo
T11	Treatment 2000 2011	response to
T12	Treatment 2041 2064	addition of tofacitinib
